Boehringer Ingelheim

C. H. Boehringer Sohn AG & Co. KG
Industry Pharmaceuticals
Founded Ingelheim am Rhein, Germany (1885 (1885))
Headquarters Ingelheim, Germany
Key people
  • Andreas Barner, Chairman of the board
  • Hubertus von Baumbach, board member
  • Wolfgang Baiker, board member
  • Allan Hillgrove, board member
  • Joachim Hasenmaier, board member
  • Andreas Neumann, board member
  • Michel Pairet, board member
Products Human Pharmaceuticals and Animal Health
Revenue Increase13,300,000,000 (2014)
Increase2,140,000,000 (2014)
Total assets Increase20,050,000,000 (2014)
Total equity Increase8,111,000,000 (2014)
Number of employees

C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key assets of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[1]


Boehringer Ingelheim works in human pharmaceuticals, animal health and biopharmaceuticals. The group consists of 145 affiliated companies with 47,500 employees in 2015 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna, Kobe, and Milan. Over 8,000 employees work for Boehringer Ingelheim in research and development.

Company History

In July 2015, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones.[2][3] On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer.[4] Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.[5]

In June 2016, the company announced it had struck an asset-swap deal with Sanofi, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders.[6] In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[7]


Collaborative research

Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[8][9] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[10]

Operational/development sites

Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993. The company's generic pharmaceutical business is vested in the Ohio, United States-based Roxane Labs subsidiary.[11]

Closure of drug manufacturing plant

In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine.[12][13] The company invested US$300,000,000 to upgrade the drug manufacturing plant, and limited production resumed in October 2012.[13] However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production."[14]

Key product lines

Prescription Medicine:

Consumer Health Care:

Animal Health:

Product pipeline

Boehringer Ingelheim's product pipeline targets lung disease, cancer, and hepatitis C.[15]

Drug Name Description Potential Indication Testing Phase
Olodaterol Long-acting beta-agonist Chronic obstructive pulmonary disease (COPD) Approved
Tiotropium Long acting muscarinic antagonist Cystic fibrosis (CF) / asthma. Already approved for chronic obstructive pulmonary disease (COPD) Approved
Nintedanib Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR Idiopathic pulmonary fibrosis (IPF) / non-small cell lung cancer (NSCLC) / ovarian cancer Phase III
Afatinib Irreversible ErbB family blocker Breast cancer / head and neck cancer. Already approved for non-small cell lung cancer (NSCLC) Phase III
Volasertib PLK1 antagonist Various cancer types Phase III
Deleobuvir (formerly BI 207127) NS5B RNA-dependent polymerase inhibitor Hepatitis C Phase III
Faldaprevir (formerly BI 201335) NS3/4A protease inhibitor Hepatitis C Phase III
Empagliflozin SGLT-2-inhibitor Diabetes mellitus type II Approved[16]
Idarucizumab Humanized antibody fragment (FAB), specific reversal agent to dabigatran Reversal of dabigatran-induced anticoagulation in case of an emergency Phase III


In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.[17]

In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.[18]

In Popular Culture The Company is mentioned as being a former place of work for one of the Characters in Season Two, Episode Ten, of the Scandinavian Police thriller Series, The Bridge (Danish/Swedish TV series).

See also


  1. "Boehringer Ingelheim Logo". Famous Logos. Retrieved 18 August 2011.
  2. Fourcade, Marthe (28 July 2015). "Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion". Bloomberg.
  3. "Hikma Buys Roxane for $2.65B, Expanding U.S. Generics Presence - GEN News Highlights - GEN".
  4. "Boehringer Licenses Hanmi Lung Cancer Drug for Up-to $730M+ - GEN News Highlights - GEN".
  5. "Boehringer dumps its Alzheimer's BACE pact with Vitae - FierceBiotech".
  6. "Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units - FiercePharma".
  7. "Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN".
  8. Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  9. "InnoMed PredTox". Genedata. InnoMed PredTox Members. Retrieved 28 November 2014.
  10. Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). EUROSFAIRE. France: Ministry of Higher Education and Research. Retrieved 2008-08-25.
  11. Staff (15 January 2015). "Boehringer May Sell U.S. Generics Unit". Pharmaceutical Manufacturing. Putman Media. Bloomberg.
  12. "Ben Venue Laboratories – Voluntary Shutdown". Drug Safety and Availability. USFDA. 30 November 2011. Retrieved 18 October 2012.
  13. 1 2 Thomas, Katie (18 October 2012). "Lapses at Big Drug Factories Add to Shortages and Danger". The New York Times. p. A1.
  14. "Ben Venue Laboratories, Inc to Cease Production" (Press release). Ben Venu Laboratories. 3 October 2013. Archived from the original on 4 October 2013.
  15. "Pipeline". Boehringer Ingelheim. Retrieved 12 September 2013.
  16. "Press Announcements - FDA approves Jardiance to treat type 2 diabetes".
  17. "Boehringer Ingelheim pays $95 million to settle whistleblower case" (Press release). Phillips & Cohen. 25 October 2012.
  18. Thomas, Katie (28 May 2014). "$650 Million to Settle Blood Thinner Lawsuits". The New York Times.

External links

This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.